Objective: This article reviews the prevalence, risk factors, natural history, and impact on quality of life of painful diabetic neuropathy (PDN) and postherpetic neuralgia (PHN).
Neuropathic pain disables millions of persons worldwide. Two of the most common forms of neuropathic pain are painful diabetic neuropathy (PDN) and postherpetic neuralgia (PHN). Although PDN is a complication of a chronic metabolic disorder (diabetes mellitus) and PHN is a complication of an acute infectious disease (herpes zoster [HZ] ), both diseases may produce significant neuropathic lesions. The objective of this article is to summarize current data on the prevalence, risk factors, natural history, and impact on quality of life of PDN and PHN.
PAINFUL DIABETIC NEUROPATHY

Diabetes mellitus
More than 14 million adults in the U.S. have diabetes mellitus. The prevalence of diabetes mellitus increases with age and has been increasing with time over the past decade in the U.S.
1,2 Table 1 shows the prevalence of diabetes mellitus in the U.S. in 1990 and 1999 by approximately 10-year age groups. The overall prevalence has increased significantly, from 4.9% in 1990 to 6.9% in 1999. This increase occurred in all age groups. The highest prevalence of diabetes mellitus in 1999 was 14.4%, in persons older than 69 years.
In 1978, Pirart 3 published data suggesting that 50% of patients with a 25-year history of diabetes mellitus will develop some form of diabetic neuropathy. The most common diabetic neuropathy is a distal sensory polyneuropathy. This article will focus on the painful variant of diabetic distal sensory polyneuropathy. 4 It is important to note that information on the epidemiology of PDN is compromised by the lack of large population-based studies and by the lack of agreement by authorities on diagnostic criteria, precise definitions, and grading severity of PDN. These problems can lead to potentially important sampling biases and measurement error.
Prevalence and risk factors
Available studies [5] [6] [7] [8] suggest that the prevalence of PDN ranges from 20% to 24% (Table 2) . Zieglar et al. 8 studied the epidemiology of diabetic neuropathy in the Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study. The study included 1,171 patients with insulin-dependent diabetes mellitus (IDDM) or noninsulin-dependent diabetes mellitus (NIDDM), who were aged 10 to 70 years and recruited from 22 centers in Germany, Switzerland, and Austria. Painful lower extremity neuropathy was noted in 75 of 647 (11.6%) IDDM patients (average duration of IDDM was 10 years) and 168 of 524 (32.1%) NIDDM patients (average duration of NIDDM was 9 years), as defined by a visual analog scale score greater than 10 mm on a 100-mm scale. Painful upper extremity neuropathy was noted in 46 of 647 (7.1%) IDDM patients and 87 of 524 (16.6%) NIDDM patients. Partanen et al. 7 studied the natural history of peripheral neuropathy among NIDDM patients in a Finnish community. At baseline, the investigators enrolled 132 newly diagnosed NIDDM patients, aged 45 to 64 at the time of diagnosis, and 142 nondiabetic control subjects. Ten years later, data were available on 86 diabetic patients and 121 control subjects. Painful diabetic neuropathy was present in 6% of diabetic patients at baseline (4% of controls) and 20% of diabetic patients after 10 years of follow-up (3% of controls).
Epidemiologic studies of diabetes mellitus have not focused on risk factors for PDN, so investigators have not clearly defined risk factors for this disorder. Diabetic cohort studies, 9, 10 however, have reported that increased age, duration of diabetes mellitus, and poorer glycemic control (elevated glycosylated hemoglobin) are risk factors for distal sensory symmetric neuropathy, and these same factors are thought to increase the risk of PDN.
Natural history
Investigators have described the natural history of PDN in small case series. In a prospective study, Boulton et al. 11 followed the cases of 39 PDN patients for 4 years. Mean pain at baseline in these patients was 5 on a 0 to 10 scale. The researchers reported no significant change in pain during the 4 years of follow-up. In another prospective study, Benbow et al. 12 followed the cases of 33 PDN patients, 9 of whom also had peripheral vascular disease, for 3.6 years. Mean pain at baseline in these patients was 4.9 (0-10 scale). By the end of follow-up, pain had worsened in 12% of the patients and improved in 88% of the patients, dropping to average pain scores of 2.0 to 2.1 (0-9.2). Seven patients eventually became pain free. Conversely, in a retrospective questionnaire study of 105 PDN patients (mean age [at the time the questionnaire was completed], 62.9 years; mean age [at the first onset of pain referable to neuropathy], 56.7 years). Galer et al. 13 noted that 71% worsened, 12% improved, and 15% stayed the same since the onset of PDN. The results of these studies conflict because of differences in samples and study designs. To better determine the course of PDN, future studies will require larger samples, a prospective design, and control for neuropathic pain treatments.
Impact on quality of life
Patients and clinicians easily describe their negative personal experience with PDN. These observations include decreased physical activity and mobility, fatigue 14 conducted a randomized, doubleblind, placebo-controlled trial of gabapentin in 162 diabetic patients with a 1-to 5-year history of PDN and a minimum pain score of 40 mm on a 100-mm visual analog scale. Health-related quality of life was measured before and after treatment using a sleep interference scale (0-10) and the SF-36 Health Survey. The baseline results before treatment showed a sleep interference score of 5.2 on the 11-point scale. Before treatment, the mean SF-36 mental health score was 69 (mean U.S. population norm is 74.74, with higher scores indicating better health). 15 The SF-36 vitality score was 41 (mean population norm, 60.86) which indicates a significant reduction in vitality.
Galer et al. 13 conducted a questionnaire mail survey of 220 community-dwelling diabetics with PDN who had inquired about participating in clinical trials for the treatment of PDN. One hundred five (48%) patients returned the survey and experienced an average pain intensity of 5.75 on a 0 to 10 pain scale. The HRQL measures were the interference items from the modified Brief Pain Inventory. Table 3 shows the mean interference scores and the percentage of patients with scores of 5 or more for each activity. Interference was greater for sleep and enjoyment of life and lesser for relations with others and self-care.
The patients in both of these studies were clinical trial volunteers. These patients may differ from other patients with PDN in demographic characteristics, ratings of pain severity, and HRQL. These studies, however, do provide some data on the nature and extent of the impact of PDN on HRQL in PDN patients with substantial pain severity.
POSTHERPETIC NEURALGIA
Herpes zoster
Investigators estimate that between 600,000 to 800,000 cases of HZ occur each year in the U.S. 16 Table  4 shows the incidence of HZ for all ages and in the elderly in the U.S. and Europe. [17] [18] [19] [20] [21] The incidence of HZ increases markedly with aging and cellular immune suppression. For example, in a recent study in Boston, investigators reported an incidence of 1.9, 2.3, 3.1, 5.7, and 11.8 per 1,000 person-years for the age groups 25-34, 35-44, 45-54, 55-64, and 65-75+ years, respectively. 17 Immunosuppressed patients at great risk for HZ include those with HIV infection, Hodgkin disease, non-Hodgkin lymphomas, leukemias, those undergoing bone marrow and other organ transplantation, and those taking immunosuppressive medications. Experts calculate the lifetime incidence of HZ to be 10% to 20% in the general population and as high as 50% of a cohort surviving to age 85 years.
Prevalence and risk factors
Three common definitions of PHN include pain one month after rash onset, pain 3 months after rash onset, or pain at rash healing. The percentage of HZ patients of all ages who develop PHN ranges from 9% to 24% when defined as pain at rash healing; 8% to 19% when defined as pain at one month after rash onset; and 8% when defined as pain at 3 months after rash onset. 22 Like HZ, the occurrence of PHN increases strikingly with aging. In Boston, patients aged 50 years or older had a 14.7-fold higher prevalence (95% CI, 6.8-32.0) of pain 30 days after rash onset compared with patients younger than 50 years. 23 Table 5 shows the prevalence of Adapted from Dworkin and Schmader. 32 PHN at different time points in adults older than 50 years who were enrolled in several HZ antiviral trials. 22 Other risk factors include greater severity of acute pain, greater rash severity, the degree of sensory impairment in the affected dermatome, psychological distress, and a painful prodrome.
22,24
Natural history
Specific data on the natural history of PHN is limited by the lack of population-based studies of zoster pain, but outpatient and antiviral studies consistently indicate that the number of HZ patients with pain declines over weeks to months from rash onset (Table 5) . 22, 25, 26 Whether treated with antiviral agents or not, a significant subset of elderly zoster patients have a poor prognosis with respect to pain. Many of these patients are refractory to multiple treatments, and some may actually get worse over time. 27 Furthermore, some patients have pain-free intervals of weeks or even months, only to note the return of their pain. Some patients with long-lasting pain eventually have a good outcome. In a study of 88 patients with PHN of one year or more, 31 (35%) had mild pain and no disability after an average of two years of follow-up. 27 
Impact on quality of life
Clinical observations indicate that PHN may profoundly impact the patient's quality of life and functional status. Postherpetic neuralgia patients can experience a variety of constitutional symptoms including chronic fatigue, anorexia, weight loss, physical inactivity, and insomnia, and psychological problems such as depression and difficulty with concentration. The social activities of PHN patients and their spouses are often curtailed by the illness and the patient's social role may change from a vital member of the community to an inactive individual in a household. Furthermore, PHN can interfere with dressing, bathing, grooming, eating, and mobility. For example, the patient with allodynic skin may be forced to avoid clothing around the affected area or bathing. Instrumental activities of daily living commonly affected include traveling, shopping, cooking, and housework.
There are few data, however, to quantify the preceding clinical observations because there are no studies that specifically describe the impact of PHN on HRQL in a cohort of patients with long-lasting pain (i.e., pain greater than 3 months). Investigators have reported data on the correlations of zoster pain and impact on HRQL in clinical trials and instrument validation studies. A generic measure of HRQL, the Nottingham Health Profile, was used to measure HRQL in a clinical trial of acyclovir and valaciclovir in 1,141 zoster patients. Mauskopf et al. 28 reported that zoster pain at 8 weeks after rash onset significantly interfered with the energy, sleep, and global quality-of-life dimensions of the Nottingham Health Profile. The magnitude of interference increased significantly as pain severity increased. For example, there were modest effects on the aforementioned dimensions when the pain unpleasantness was rated as annoying but very strong effects when the pain was rated as very distressing or intolerable. In a prospective observational study of 121 outpatients aged 60 years or older with HZ, Coplan et al. 29 correlated the Zoster Brief Pain Inventory, a zoster-specific measure of pain and interference with activities, with the SF-12 and EuroQOL HRQL measures and an activities of daily living (ADL) questionnaire. Using the 0 to 10 worst-pain score, zoster pain at 35 days and 70 days after rash onset significantly interfered with multiple ADLs, reduced global quality of life, as measured by the EuroQol, and impaired mental and physical health, as measured by the SF-12. As with the Mauskopf study, interference with ADLs and reduced HRQL increased significantly as pain severity increased.
CONCLUSIONS
Painful diabetic neuropathy and PHN are common complications of diabetes mellitus and HZ, respectively. Data are limited on risk factors and the natural history of PDN, but duration of diabetes mellitus and poor glycemic control are probably important factors. Aging, greater pain and rash severity, greater degree of sensory impairment, and psychological distress are risk factors for PHN. These conditions degrade quality of life and disable affected persons via their negative impact on the physical, psychological, social, and functional health of those affected. The magnitude of the impact on quality of life increases with increasing pain severity.
